Last reviewed · How we verify
NCT06585150
Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
Phase 2 trial testing Obeldesivir in RSV Infection in 150 participants. Terminated before completion.
8 May 2025
Quick facts
| Lead sponsor | Gilead Sciences |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 14 October 2024 |
| Primary completion | 8 May 2025 |
| Estimated completion | 9 June 2025 |
| Sites | 121 locations across United States |
Drugs / interventions tested
- Obeldesivir — full drug profile →
- Obeldesivir Placebo — full drug profile →
Conditions studied
- RSV Infection — all drugs for RSV Infection →
Sponsor
Gilead Sciences — full company profile →
Who can join
18 and older, any sex, with RSV Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical study is to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it is in treating nonhospitalized adults with acute respiratory syncytial virus (RSV) infection. The researchers want to see if obeldesivir can help participants' symptoms get better faster. The primary objectives of this study are to evaluate the efficacy of ODV in reducing the duration of symptoms and to evaluate the safety and tolerability of ODV in nonhospitalized adult participants with acute RSV infection.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeys.
Pitts J, Zamora JLR, Manhas S, Aeschbacher T, et al · · 2025 · cited 1× · PMID 40645925 · DOI 10.1038/s41467-025-61595-3
Verify or expand the search:
- PubMed search for NCT06585150
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Obeldesivir
Trials testing the same drug.
- NCT06784973 — Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection · Phase 2 · terminated
- NCT05996744 — Study of Obeldesivir in Children and Adolescents With COVID-19 · Phase 2, PHASE3 · terminated
- NCT05715528 — Study of Obeldesivir in Nonhospitalized Participants With COVID-19 · Phase 3 · completed
- NCT05603143 — Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness · Phase 3 · terminated
Other recruiting trials for RSV Infection
Currently open trials in the same condition.
- NCT06881953 — Prevention Strategy for Respiratory Syncytial Virus (RSV) Infections in Infants in France · recruiting
- NCT06866405 — A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Sin · Phase 3 · recruiting
- NCT06843317 — Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults · Phase 1 · recruiting
- NCT06172660 — Real-World Effectiveness of Perinatal RSV Immunoprophylaxis · recruiting
- NCT06640387 — CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools · recruiting
Other Gilead Sciences trials
Trials by the same sponsor.
- NCT07115368 — Study of GS-1219 in Participants With HIV-1 · Phase 1 · terminated
- NCT06784973 — Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection · Phase 2 · terminated
- NCT06683482 — A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in Spain · completed
- NCT06613685 — Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated · Phase 2, PHASE3 · terminated
- NCT05996744 — Study of Obeldesivir in Children and Adolescents With COVID-19 · Phase 2, PHASE3 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06585150 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gilead Sciences
- Last refreshed: 28 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06585150.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing